The active molecule is the same. Ozempic contains semaglutide; Mounjaro contains tirzepatide. What sets Genotech apart is the origin — Canadian laboratory synthesis with HPLC analysis on every lot — and the format: a lyophilised vial requiring reconstitution, not a pre-filled pen. Same molecular mechanism, different format, full traceability.

Not to access the product, but professional supervision is strongly recommended. These compounds require gradual titration, dose adjustment, and attention to how the body responds. If you do not currently have a treating physician, our team can refer you to professionals experienced in this area.

As with any active molecule, yes. The most common with GLP-1 compounds are mild nausea, changes in digestion, and occasionally fatigue during the first week of each titration step. The way to minimise them is gradual titration: we always start at the lowest dose for four weeks before stepping up. The full protocol is provided with your order.

It is a real possibility if the protocol is not paired with sustainable behaviour change. These molecules regulate appetite while they are being applied; once discontinued, appetite returns toward its baseline. For that reason, we provide a maintenance guide alongside the protocol and recommend a gradual taper rather than an abrupt stop.

Semaglutide acts on a single receptor (GLP-1). It is the most studied option and is the gentlest entry point. Tirzepatide acts on two receptors (GIP + GLP-1) and tends to show more pronounced results in less time. Retatrutide acts on three (GIP + GLP-1 + glucagon) and is the most recent generation. The right choice depends on your starting point, expectations, and tolerance. Our team can help you decide.